RXDX News and Press, Prometheus Biosciences Inc. From 03/01/22

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for th...

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the...

Are These The Best Health Care Stocks To Invest In Right Now? As investors consider the current state of the stock market now, health care stocks could become increasingly viable plays. Overall, this would be understandable seeing as markets are having a mostly rocky start t...

- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheus’ precision approach and e...

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the...

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the...

3 Top Biotech Stocks To Check Out Right Now Like it or not, biotech stocks are becoming an increasingly viable play in the stock market today. By and large, this remains the case as the current coronavirus pandemic lit a fire under the industry. Namely, both seasoned and new investo...

Prometheus displays positive phase 1 safety data with PRA023. Drug also shows target engagement with mode of action in healthy volunteers. Based on the phase 1 data, biotech has added a 3rd indication for PRA023, which is Systemic Sclerosis-Associated Lung disease. Phase 1 study to st...

Prometheus Biosciences (NASDAQ:RXDX) has added ~4.2% in the pre-market after announcing that its Phase 1 trial for lead candidate PRA023 reached the primary objective of safety and tolerability among healthy volunteers. “Our design objective for PRA023 was to develop a compet...

Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in c...